The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...
Supernus Pharmaceuticals, Inc. announced that the FDA has approved an updated label for Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data, highlighting its ...
Qelbree ® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals ...
Qelbree has helped me manage my ADHD symptoms, and I have Supernus to thank for that.” October is ADHD Awareness Month, an important time to bring attention to the often complicated diagnosis ...
The new information in Section 12.2 of the label details Qelbree's partial agonist activity at the serotonin 5-HT2C receptor and its inhibition of the norepinephrine transporter. This multimodal ...
MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback